×
AllNewsImagesVideos Maps Shopping Books
Search tools
Archives
  • Recent
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
  • Archives
Sorted by relevance
Clear

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

The New England Journal of Medicine
Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal...
95 months ago

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet
We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.
68 months ago

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Frontiers
The aim of this study was to evaluate risankizumab-associated adverse events (AEs) and characterize the clinical priority through the data mining of the Food...
22 months ago

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis

Wiley Online Library
What is already known about this topic? In clinical trials of patients with moderate-to-severe plaque psoriasis, risankizumab,...
41 months ago

Risankizumab Under Review for Moderately to Severely Active Ulcerative Colitis

Medical Professionals Reference
AbbVie has submitted a regulatory application to the Food and Drug Administration (FDA) seeking approval of risankizumab for the treatment of adults with...
19 months ago

Risankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA

HCPLive
Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.
12 months ago

Risankizumab in CD: Outcomes Remain Stable up to 3 Years

Medscape
Long-term data on risankizumab (Skyrizi) in moderate to severe Crohn's disease (CD) show that clinical remission and endoscopic response rates remain stable...
13 months ago

FDA gives AbbVie’s Skyrizi a Thumbs-Up for Plaque Psoriasis

BioSpace
AbbVie announced the US Food and Drug Administration (FDA) had approved its Skyrizi (risankizumab-rzaa) for severe plaque psoriasis in adults.
71 months ago

Risankizumab Meets All Endpoints Vs Ustekinumab for Crohn's Disease Advances | Gastroenterology

HMP Global Learning Network
Risankizumab met all primary and secondary endpoints including noninferiority to ustekinumab for inducing clinical remission among patients with moderate to...
17 months ago

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

PR Newswire
PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study,...
5 months ago